|
USA-731917-AdvertisingComputer Directorios de empresas
|
Noticias de la compañía :
- Nexletol shows CLEAR benefit in cardiovascular outcome trial
New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Broader Adoption of SGLT2 Inhibitors in Clinical Practice
Over the past decade, the indications for sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney and cardiovascular risk reduction have expanded, driven by clinical trial evidence demonstrating their efficacy among individuals with chronic kidney disease (CKD), heart failure, diabetes, and
- NEXLIZET® NEXLETOL® Other Outcomes Trial Information
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
- Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores . . .
Background: Cardiovascular disease (CVD) is a leading cause of mortality in Type 2 diabetes mellitus (T2DM) Sodium-glucose co-transporter 2 (SGLT2) inhibitors are known to provide cardioprotective effects, but their influence on validated cardiovascular risk models remains underexplored This study assessed the impact of SGLT2 inhibitors on cardiovascular risk scores, metabolic parameters
- Therapeutic Value of SGLT2 Inhibitors in the Management of . . .
SGLT2 inhibitors have transformed the treatment of cardiovascular disease, providing substantial therapeutic promise for a wide range of patients They are anticipated to become more and more important in the prevention and management of cardiovascular disease
- FinancialContent - Esperion Showcases New Data from CLEAR . . .
“These new analyses from CLEAR Outcomes further strengthen the evidence base supporting NEXLETOL as a proven therapy for cardiovascular risk reduction - especially for patients who cannot tolerate statin therapy,” said Sheldon Koenig, President and Chief Executive Officer of Esperion
- FDA approves broad new labels for Nexletol ( bempedoic acid . . .
Esperion announced that the FDA has approved broad new label expansions for Nexletol (bempedoic acid) Tablets and Nexlizet (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients
- Larvol Delta - SGLT2-inhibitors-an-EvidenceBased-Update-on . . .
quot;High-dose statins, ezetimibe, PCSK 9 inhibitors, and bempedoic acid are the recommended therapies for LDL reduction in ACS patients Despite the proven effect of these lipid-lowering therapies, undertreatment is still a big hurdle across the globe Prohibitive costs, adverse effects, medication non-adherence, variation in health practice in different countries, and clinical inertia to
|
|